Observational studyAmerican journal of respiratory and critical care medicine2021
Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
Open access · hybridAbstract readObservational Study
In one paragraph
Observational study in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- Influenza coinfection inhibits control of mycobacterial infection in a human challenge model.Nature communications · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- A PTPRO-Related Five-Gene Blood Transcriptional Signature with Diagnostic Potential for Tuberculosis.Biomedicines · 2026Article
- Article
- Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification.Frontiers in cell and developmental biology · 2026Review
- Virus profiling of bronchoalveolar lavage fluid in hospitalized non-COVID-19 adult patients with pulmonary infection from November 2020 to November 2021.Virologica Sinica · 2025Article
- Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent.mSphere · 2025Article
- Transcriptomic Signatures of Progression to Tuberculosis Disease Among Close Contacts in Brazil.The Journal of infectious diseases · 2024Article
- Unmasking the hidden impact of viruses on tuberculosis risk.Trends in immunology · 2024Review
- Age and sex influence antibody profiles associated with tuberculosis progression.Nature microbiology · 2024Article
- Blood RNA biomarkers for tuberculosis screening in people living with HIV before antiretroviral therapy initiation: a diagnostic accuracy study.The Lancet. Global health · 2024Article
- A half-century of research on tuberculosis: Successes and challenges.The Journal of experimental medicine · 2023Article
- Identification of cuproptosis-related molecular subtypes as a biomarker for differentiating active from latent tuberculosis in children.BMC genomics · 2023Article
- Blood RNA biomarkers for tuberculosis screening in people living with HIV prior to anti-retroviral therapy initiation: A diagnostic accuracy study.medRxiv : the preprint server for health sciences · 2023Article
- Culture independent markers of nontuberculous mycobacterial (NTM) lung infection and disease in the cystic fibrosis airway.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants.Nature communications · 2022Article
- Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all?EBioMedicine · 2022Review
- Mind the gap - Managing tuberculosis across the disease spectrum.EBioMedicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
34 authors at 8 institutions in 4 countries.
Humphrey MulengaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Munyaradzi MusvosviSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Simon C MendelsohnSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.ORCID 0000-0002-4054-2766
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Stanley Kimbung MbandiSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Andrew Fiore-GartlandVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0001-7627-2166
Michèle TamerisSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Simbarashe MabweSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Hadn AfricaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Nicole BilekSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Fazlin KafaarSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Shabaana A KhaderDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri.
Balie CarstensSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Katie HadleySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Chris HikuamSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Mzwandile ErasmusSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Lungisa JaxaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Rodney RaphelaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Onke NombidaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Masooda KaskarSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.
Mark P NicolDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Slindile MbheleDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Judi Van HeerdenDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Craig InnesThe Aurum Institute, Johannesburg, Guateng, South Africa.
William BrumskineThe Aurum Institute, Johannesburg, Guateng, South Africa.
Andriëtte HiemstraDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Stephanus T MalherbeDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Razia Hassan-MoosaCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Gerhard WalzlDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Kogieleum NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Gavin ChurchyardThe Aurum Institute, Johannesburg, Guateng, South Africa.
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.ORCID 0000-0003-3491-1809
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, and.ORCID 0000-0002-0641-1359
CORTIS Study Team
TuBerculosis Vaccine Initiative · NLNational Research Foundation · ZAUniversity of Cape Town · ZAAurum Institute · ZACentre for the AIDS Programme of Research in South Africa · ZAFred Hutch Cancer Center · USUniversity of the Witwatersrand · ZAWashington University in St. Louis · US
Funding
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4MAurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1MHIV-associated Tuberculosis Training Program (HATTP)D43TW010559 · FIC · UNIVERSITY OF CAPE TOWN · PI Graeme Ayton Meintjes · 2017 to 2026
$3.0MCOMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANSR01AI123780 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2016 to 2019
$2.9MFIC NIH HHS D43 TW010559NIAID NIH HHS R01 AI123780NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI154463
Abstract
PubMed holds no abstract for this paper.
Indexed as
Clinical Decision RulesGene Expression ProfilingTranscriptomeAdolescentAdultAnti-HIV AgentsAntitubercular AgentsBiomarkersCoinfectionCross-Sectional StudiesFemaleHIV InfectionsHumansLinear ModelsLongitudinal StudiesMaleAnti-HIV AgentsAntitubercular AgentsBiomarkersbiomarkersHIVmRNAMycobacterium tuberculosisrespiratory tract infections
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.